Benzinga | Sep 21, 2020 07:08AM EDT

Cyclacel Announces Fadraciclib Abstract Selected For Oral Presentation In The Late Breaking And Best Proffered Paper Session At 32nd EORTC-NCI-AACR Symposium 2020 Sat. Oct. 24

BERKELEY HEIGHTS, N.J., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced that an abstract highlighting clinical data with Cyclacel's CDK2/9 inhibitor fadraciclib has been selected for an oral presentation at the32nd EORTC-NCI-AACR (ENA) Symposium 2020 being held virtually onOctober 24--25, 2020. The data is from an ongoing Phase 1 study of fadraciclib as a single agent in patients with advanced solid tumors.



Details for the presentations are as follows:

Title:Phase 1 safety, pharmacokinetic and pharmacodynamic study of fadraciclib (CYC065), a cyclin dependent kinase inhibitor, in patients with advanced cancers (NCT02552953)

Session Title:Late Breaking and Best Proffered Papers

Session Date and Time: Saturday 24 October 15:05 CET

Presentation Number: ORAL-002

The program can be accessed through the EORTC-NCI-AACR website.